Top Buy Stocks
Sign In
NASDAQ:ADAP
Adaptimmune Therapeutics Plc Stock Earnings Reports
Invest in ADAP
$0.280
+0.0057 (+2.08%)
At Close: May 23, 2025
Adaptimmune Therapeutics plc Earnings Calls
Q1 2025
| Release date | May 13, 2025 |
| EPS estimate | -$0.180 |
| EPS actual | -$0.180 |
| Revenue estimate | 8.66M |
| Revenue actual | 7.285M |
| Revenue Surprise | -15.88% |
Q4 2024
Missed
-$0.260 (-52.94%)
| Release date | Mar 24, 2025 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.260 |
| EPS Surprise | -52.94% |
| Revenue estimate | 8.419M |
| Revenue actual | 3.222M |
| Revenue Surprise | -61.73% |
Q3 2024
Beat
-$0.0700 (58.82%)
| Release date | Nov 13, 2024 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.0700 |
| EPS Surprise | 58.82% |
| Revenue estimate | 11.17M |
| Revenue actual | 40.901M |
| Revenue Surprise | 266.17% |
Q2 2024
Beat
$0.240 (442.86%)
| Release date | Aug 12, 2024 |
| EPS estimate | -$0.0700 |
| EPS actual | $0.240 |
| EPS Surprise | 442.86% |
| Revenue estimate | 11.17M |
| Revenue actual | 12.823M |
| Revenue Surprise | 14.80% |
Last 4 Quarters for Adaptimmune Therapeutics plc
Below you can see how ADAP performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Beat
| Release date | Aug 12, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $1.09 |
| EPS estimate | -$0.0700 |
| EPS actual | $0.240 |
| EPS surprise | 442.86% |
| Date | Price |
|---|---|
| Aug 06, 2024 | $1.00 |
| Aug 07, 2024 | $1.01 |
| Aug 08, 2024 | $0.99 |
| Aug 09, 2024 | $0.99 |
| Aug 12, 2024 | $1.09 |
| Aug 13, 2024 | $1.05 |
| Aug 14, 2024 | $1.04 |
| Aug 15, 2024 | $1.09 |
| Aug 16, 2024 | $1.08 |
| 4 days before | 9.00% |
| 4 days after | -0.92% |
| On release day | -3.67% |
| Change in period | 8.00% |
Q3 2024
Beat
| Release date | Nov 13, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $0.771 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.0700 |
| EPS surprise | 58.82% |
| Date | Price |
|---|---|
| Nov 07, 2024 | $0.777 |
| Nov 08, 2024 | $0.797 |
| Nov 11, 2024 | $0.82 |
| Nov 12, 2024 | $0.794 |
| Nov 13, 2024 | $0.771 |
| Nov 14, 2024 | $0.591 |
| Nov 15, 2024 | $0.587 |
| Nov 18, 2024 | $0.595 |
| Nov 19, 2024 | $0.675 |
| 4 days before | -0.81% |
| 4 days after | -12.43% |
| On release day | -23.28% |
| Change in period | -13.14% |
Q4 2024
Missed
| Release date | Mar 24, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $0.277 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.260 |
| EPS surprise | -52.94% |
| Date | Price |
|---|---|
| Mar 18, 2025 | $0.455 |
| Mar 19, 2025 | $0.449 |
| Mar 20, 2025 | $0.280 |
| Mar 21, 2025 | $0.291 |
| Mar 24, 2025 | $0.277 |
| Mar 25, 2025 | $0.250 |
| Mar 26, 2025 | $0.230 |
| Mar 27, 2025 | $0.220 |
| Mar 28, 2025 | $0.206 |
| 4 days before | -39.18% |
| 4 days after | -25.58% |
| On release day | -9.68% |
| Change in period | -54.74% |
Q1 2025
| Release date | May 13, 2025 |
| Fiscal end date | Mar 31, 2025 |
| Price on release | $0.250 |
| EPS estimate | -$0.180 |
| EPS actual | -$0.180 |
| Date | Price |
|---|---|
| May 07, 2025 | $0.300 |
| May 08, 2025 | $0.300 |
| May 09, 2025 | $0.293 |
| May 12, 2025 | $0.295 |
| May 13, 2025 | $0.250 |
| May 14, 2025 | $0.272 |
| May 15, 2025 | $0.265 |
| May 16, 2025 | $0.278 |
| May 19, 2025 | $0.291 |
| 4 days before | -16.67% |
| 4 days after | 16.52% |
| On release day | 8.80% |
| Change in period | -2.90% |
Adaptimmune Therapeutics plc Earnings Call Transcript Summary of Q1 2025
Summary of Key Points from Adaptimmune's Q1 2025 Earnings Call for Investors
- TECELRA Launch Success:
- Adaptimmune has reported positive momentum in the launch of its cell therapy product, TECELRA, with revenue guidance for 2025 set between $35 million and $45 million.
- In Q1 2025, 21 patients were aphereseed, with 13 in Q1 and 8 anticipated in early Q2.
- The company invoiced 14 treatments for TECELRA to date in 2025, with net sales of $4 million reported for Q1.
- Healthcare Infrastructure and Patient Access:
- There are 28 authorized treatment centers (ATCs) currently accepting patient referrals, with a plan to have approximately 30 centers operational by the end of 2025, ahead of schedule.
- Patient access has been strong, with no denials from payers reported since launch.
- Manufacturing Efficiency:
- The firm achieved 100% manufacturing success from its Philadelphia center, with an average turnaround time from apheresis to lot release currently at 27 days, which is ahead of their target of 30 days.
- Future Product Strategy:
- The company is preparing for the launch of lete-cel, anticipated in 2026, which could significantly expand the sarcoma patient population.
- Lete-cel is expected to address two additional indications, synovial sarcoma and myxoid round cell liposarcoma, simplifying patient access due to anticipated lower testing requirements.
- Market Dynamics and Financial Position:
- Adaptimmune remains proactive in exploring strategic options, having engaged Cowen as advisors for potential future endeavors benefiting both patients and shareholders.
- The company is managing its financial obligations, evidenced by a recent $25 million debt paydown to strengthen its balance sheet.
- Despite a liquidity concern highlighted in their 10-K filing, the cash runway remains intact due to thoughtful management of expenses and ongoing operational efficiencies.
- Patient Trends:
- The treatment regimen has been aligned with earlier expectations regarding patient identifiers and treatment rates, with nearly 100% of patients that undergo apheresis receiving infusion to date.
- The pace of patient referrals and subsequent treatments is expected to continue to grow, supported by increased awareness and the buildup of ATCs.
This summary provides a snapshot of Adaptimmune's current operational status, outlook, and strategic initiatives, offering investors key insights for decision-making.
Adaptimmune Therapeutics plc Earnings History
Earnings Calendar
FAQ
When is the earnings report for ADAP?
Adaptimmune Therapeutics plc (ADAP) has scheduled its earnings report for Aug 11, 2025 before the markets open.
What is the ADAP price-to-earnings (P/E) ratio?
ADAP P/E ratio as of May 23, 2025 (TTM) is -1.03.
What is the ADAP EPS forecast?
The forecasted EPS (Earnings Per Share) for Adaptimmune Therapeutics plc (ADAP) for the first fiscal quarter 2025 is -$0.110.
What are Adaptimmune Therapeutics plc's retained earnings?
On its balance sheet, Adaptimmune Therapeutics plc reported retained earnings of $7.29 million for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
